Fundraising Fox

Junevity

Founded 2023 · 13 employees on LinkedIn · 2 known investors

Find your way into Junevity

651 people in our graph share verified history with the Junevity team — schools, employers, funds. One of them is your warm intro.

Laura Buhlerunlockedknows Rob Cahill · together at McKinsey & Company (overlapped)
×4knows the team · via McKinsey & Company
×2knows the team · via University of California, San Francisco
×2knows the team · via California Polytechnic State University-San Luis Obispo
knows the team · via UCSF
knows the team · via SunRun

Junevity is a biotech company developing siRNA therapeutics based on its RESET platform, which uses transcription factor repression to restore healthy gene expression and target age-related diseases. The company applies bioinformatics, machine learning, and cellular aging research to develop treatments for metabolism and aging-related conditions.

AI & Machine LearningBiotechDeep TechLongevity

Founders & leadership

Junevity was founded in 2023 by John Hoekman, Janine Sengstack, Rob Cahill, and Hao Li.

JHJohn Hoekman
John HoekmaninCo-founder & CEOExecutive Officer, Director at Impel Neuropharma
JSJanine Sengstack
Janine SengstackinCo-founder & CSOJanine Sengstack is co-founder and chief scientific officer of Junevity, a biotech company developing siRNA therapeutics for age-related diseases. She completed her PhD at UC San Francisco, where she worked with Dr. Hao Li on identifying genes associated with cellular aging and developed high-throughput methods for target discovery and validation.
RCRob Cahill
Rob CahillinCo-founder, COO & CBORob Cahill is co-founder and COO/CBO of Junevity, a biotech company developing siRNA therapeutics for age-related diseases that launched from UCSF in 2023.
HLHao Li
Hao LiinCo-founder & UCSF ProfessorHao Li is a professor of biology at UCSF and director of the Hillblom Center for Biology of Aging, with a Ph.D. in theoretical physics from MIT. His research centers on aging mechanisms, systems biology, and human genetics, and he co-founded Junevity to develop siRNA-based therapeutics targeting age-related diseases.

Investors · 2

Goldcrest Capital✓ verifiedDallas
Type One VenturesLos Angeles · $100K – $5M

Funding

SEC filings, press & company announcements

$20M disclosed across 1 of 3 rounds · 2025

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 2

by search overlap
Revvity20 shared keywordsRevvity develops and sells reagents, instruments, software, and services for life sciences research and clinical diagnostics, serving pharmaceutical, biotech, academic and government institutions across drug discovery, development, and disease diagnosis workflows.
Bionity5 shared keywordsBionity.com is a German-language B2B trade portal for the life sciences, biotechnology, and pharmaceutical industries, offering news, trends, supplier directories, job listings, and lab and production solutions. Operated by LUMITOS AG, it serves professionals in industry, research, and science and provides online marketing services to reach this B2B audience.

Companies competing with Junevity for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Trysignalbasetrysignalbase.com · Dec 2025Metabolic biotech Junevity raises $10M, doubling seed round to $20Maxios.com · Dec 2025Junevity Expands Seed Funding to $20 Million for Cell Reprogramming with siRNAbusinesswire.com · Dec 2025PRESS RELEASE — Junevity – Cell Reset for Longevityjunevity.com · Feb 2025Junevity Raises $10M to Develop Cell Reset Therapeutics for Longevitybusinesswire.com · Feb 2025Junevity Raises $10M in Seed Fundingfinsmes.com · Feb 2025

Frequently asked questions

What does Junevity do?
Junevity is a biotech company developing siRNA therapeutics based on its RESET platform, which uses transcription factor repression to restore healthy gene expression and target age-related diseases. The company applies bioinformatics, machine learning, and cellular aging research to develop treatments for metabolism and aging-related conditions.
Who founded Junevity?
Junevity was founded by John Hoekman, Janine Sengstack, Rob Cahill, Hao Li in 2023.
Who are Junevity's investors?
Junevity's investors include Goldcrest Capital, Type One Ventures.
How much funding has Junevity raised?
Junevity has disclosed $20M raised across 1 of its 3 known rounds.